Completed PHASE4 INTERVENTIONAL NCT00001520

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

Sponsor: National Institutes of Health Clinical Center (CC)

Conditions Paralysis

Interventions neostigmine

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Sep 30, 1996 Completion: Aug 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00001520, this PHASE4 trial focuses on Paralysis and remains completed. Sponsored by National Institutes of Health Clinical Center (CC), it has been updated 5 times since 1996, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institutes of Health Clinical Center (CC)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States